Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Lymphoma 200Leukemia 159Leukemia, Myeloid, Acute 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Lymphoma, Non-Hodgkin 111Multiple Myeloma 110Lymphoma, Large B-Cell, Diffuse 108Lymphoma, Follicular 93Hodgkin Disease 91Burkitt Lymphoma 91Myelodysplastic Syndromes 87Lymphoma, Mantle-Cell 87Leukemia, Lymphocytic, Chronic, B-Cell 84Breast Neoplasms 84Lymphoma, Large-Cell, Immunoblastic 73Lymphoma, B-Cell, Marginal Zone 59Sarcoma 54Neoplasms, Plasma Cell 50Neuroblastoma 49Central Nervous System Neoplasms 46Leukemia, Myeloid, Chronic-Phase 43Recurrence 40Ovarian Neoplasms 39Leukemia, Myeloid, Accelerated Phase 39Congenital Abnormalities 39Myeloproliferative Disorders 38Dendritic Cell Sarcoma, Interdigitating 38Blast Crisis 34Leukemia, Myelomonocytic, Chronic 32Neutropenia 29

Interventions

Imatinib Mesylate 5venetoclax 1ruxolitinib 1pevonedistat 1nilotinib 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Dasatinib 1Cytarabine 1Cladribine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypereosinophilic Syndrome × Filgrastim × Clear all
NCT00483067 2012-08-02

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

M.D. Anderson Cancer Center

Phase 2 Completed
13 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡